Lyme Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The lyme disease market reached a value of USD 674.5 Million across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1,369.4 Million by 2036, exhibiting a growth rate (CAGR) of 6.70% during 2026-2036.

The Lyme disease market has been comprehensively analyzed in IMARC's new report titled "Lyme Disease Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Lyme disease is a vector-borne illness caused by a bacteria called Borrelia burgdorferi. This condition is transmitted to humans by the bites of infected ticks of the species Ixodes. The disease is usually characterized by an expanding, non-painful red rash, named erythema migrans, which develops at the site of the tick bite after around a week. The common symptoms associated with the ailment include rash, fever, headache, extreme tiredness, swollen lymph nodes, etc. In severe cases, patients may also experience joint pain, impaired ability to move one or both sides of the face, neck stiffness, headaches, memory difficulty, or heart palpitations. The diagnosis of this disorder typically involves a combination of an objective physical examination, a review of the patient's medical history for possible exposure to infected ticks, and laboratory investigations. A blood antibody test using enzyme-linked immunosorbent assay (ELISA) and western blot is primarily performed to diagnose Lyme disease. The healthcare provider may also recommend polymerase chain reaction (PCR) tests to detect the presence of bacterial genetic material in the body.

The rising cases of tick-borne diseases owing to the increasing tick exposure through outside activities, such as gardening, hunting, hiking, etc., are primarily driving the Lyme disease market. Additionally, the widespread adoption of antibiotics and nonsteroidal anti-inflammatory drugs to help relieve pain and reduce inflammation associated with the ailment is further propelling the market growth. Moreover, the emerging popularity of advanced diagnostic tests, including T-Detect Lyme, which identifies an immune response by activated T-cells against bacteria to provide early disease diagnosis, is acting as another significant growth-inducing factor. Apart from this, the rising usage of non-pharmaceutical interventions, such as cognitive behavioral therapy and acupuncture, to help improve functional disability and cope with the psychological effects of the condition is also augmenting the market growth. Furthermore, the escalating demand for mesenchymal stem cell therapy owing to its potent immunomodulatory and anti-inflammatory properties, which can reduce the severity of underlying symptoms and promote tissue repair, is creating a positive outlook for the market. Besides this, the increasing utilization of immunomodulatory therapies, including low-dose naltrexone and immune-modulating peptides, to regulate the immune system and enhance its ability to fight the infection is expected to drive the Lyme disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Lyme disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Lyme disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Lyme disease market in any manner.

Recent Developments:

• In March 2026, Pfizer and Valneva announced that their Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above in the Phase 3 VALOR trial. The investigational vaccine was well tolerated with no safety concerns identified at the time of analysis, and the results strengthened confidence in the candidate, with plans underway for regulatory submissions.
• In March 2026, Tonix Pharmaceuticals announced the presentation of Phase 1 data for its Lyme disease prevention candidate TNX-4800 (formerly mAb 2217LS) at the World Vaccine Congress Washington 2026. The data were presented by Mark S. Klempner, principal investigator of the study, and demonstrated early-stage clinical evaluation of the candidate for preventing Lyme disease. The company also outlined plans to initiate an adaptive Phase 2 field study in the first half of 2027, pending clearance from the U.S. Food and Drug Administration.

Key Highlights:

• Lyme disease remains one of the most common tick-borne infections across Europe, with studies indicating that approximately 1% to 5% of tick bites can result in infection.
• In England and Wales, around 4% to 6% of ticks are infected on average, although infection rates can rise to between 7% and 10% in certain regions and vary by year.
• There are roughly 1,500 laboratory-confirmed Lyme disease cases reported annually in England and Wales; however, total estimated cases range from 3,000 to 4,000 per year, as many infections are treated clinically without laboratory confirmation.
• In the United States, over 89,000 Lyme disease cases were officially reported to the Centers for Disease Control and Prevention by state health departments and the District of Columbia in 2023 .
• However, estimates from the Bay Area Lyme Foundation suggest that more than 620,000 individuals are diagnosed with Lyme disease annually, highlighting substantial underreporting in official surveillance systems. 

Drugs:

VLA15 is an investigational Lyme disease vaccine candidate developed by Pfizer and Valneva. This experimental multivalent protein subunit vaccine utilizes a well-established mechanism of action for a Lyme disease vaccine by targeting the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Lyme disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Lyme disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Lyme disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Lyme disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the Lyme disease across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the Lyme disease across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2020-2036) of Lyme disease across the seven major markets?
• What is the number of incident cases (2020-2036) of Lyme disease by age across the seven major markets?
• What is the number of incident cases (2020-2036) of Lyme disease by gender across the seven major markets?
• What is the number of incident cases (2020-2036) of Lyme disease by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with Lyme disease across the seven major markets?
• What is the size of the Lyme disease patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend Lyme disease of?
• What will be the growth rate of patients across the seven major markets?

Lyme Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Lyme disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Lyme disease market?
• What are the key regulatory events related to the Lyme disease market?
• What is the structure of clinical trial landscape by status related to the Lyme disease market?
• What is the structure of clinical trial landscape by phase related to the Lyme disease market?
• What is the structure of clinical trial landscape by route of administration related to the Lyme disease market?